摘要
目的探讨血小板减少对判断骨髓增生异常综合征(MDS)患者预后的意义。方法回顾性分析419例原发性MDS患者临床资料,应用Kaplan—Meier、Log—rank检验及COX回归模型评估影响预后的因素。结果419例MDS患者中血小板减少(PLT〈10×10^9/L)者256例(61.1%),严重减少(PLT〈30×10^9/L)者103例(24.6%)。PⅡ≥100×10^-9/L组、(50—99)×10^9/L组、(30~49)×10^9/L组和〈30×10^9/L组患者中位生存时间分别为41、38、19和17个月,差异有统计学意义(P=0.000)。单因素分析显示PLT〈30×10^9/L、红细胞平均体积(MCV)≤95fl、LDHI〉300U/L、有淋巴样小巨核细胞、有核红细胞糖原染色(E-PAS)阳性、国际预后积分系统(IPSS)染色体核型预后中等及不良为MDS不良预后因素;WHO分型中难治性血细胞减少伴有多系发育异常(RCMD)、难治性贫血伴有原始细胞过多(RAEB)一I及RAEB-11的患者较其他类型的患者预后差。多因素分析显示PLT〈30×10^9/L,MCV≤95fl,IPSS染色体核型预后中等及不良,WHO分型RCMD、RAEB-I及RAEB-II具有独立预后意义。修订的WHO分型预后积分系统(WPSS)各参数赋值如下:PLT〈30×10^91分,其他0分;MCV≤95fl 1分,其他0分;染色体核型良好0分,中等1分,不良2分;WHO分型中RCMD1分,RAEB—I2分,RAEB一Ⅱ3分,其他0分。患者分为低危(0—1分)、中危-1(2—3分)、中危-2(4—5分)和高危组(6~7分),其中位生存期分别为59、28、14和4个月,各组间差异具有统计学意义(P值均〈0.05)。结论血小板严重减少的MDS患者预后不良,结合血小板计数、染色体核型、MCV及修订的WPSS有望更好地促进我国MDS患者分组治疗策略的制订。
Objective To investigate the prognostic value of thrombocytopenia in patients with pri- mary myelodysplastic syndromes(MDS). Methods Four hundred and nineteen primary MDS patients were retrospectively analyzed. Kaplan-Meier method, Log-rank test and COX regression model were used to evalu- ate factors that influence the prognosis. Results Two hundred and fifty-six cases (61.1% ) had thrombocyto- penia(PLT 〈 100×10^9/L), one hundred and three cases (24.6%) had severe thrombocytopenia(PLT 〈 30 ×10^9/L). Overall survival (OS) tended to shorten along with the decreasing of platelet count. Univariate analysis indicated that PLT 〈 30 ×10^9/L, MCV 〈95 fl, LDH 〉1300 U/L, lymphocyte-like mieromegakaryo- cyte, nucleated RBC PAS positive, IPSS cytogenetic intermediate- and poor-risk were all related with poor prognosis. Moreover, the prognosis of patients with RCMD, RAEB- I or RAEB- lI was poorer than that of the other subgroups. Among these parameters, PLT 〈 30 x 109/L, MCV 〈~95 fl, IPSS cytogenetic intermediate- and poor-risk group and RCMD, RAEB- I and RAEB- II had independent prognostic significance in multiva- riate analysis. Modified WPSS prognostic model was proposed by adopting PLT, MCV, chromosomal karyo- type and WHO classification. The OS of patients with low risk, intermediate-1 risk, intermediate-2 risk and high risk were 59, 28, 14 and 4 months, respectively, and there was a statistically significant difference be- tween the groups ( P 〈 0. 05 ). Conclusion Severe thrombocytopenia indicated unfavorable prognosis, in combination with MCV, chromosomal karyotype and WHO classification, a modified WPSS prognostic model was proposed and worked well for prognostic indication in patients with MDS.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2012年第7期532-535,共4页
Chinese Journal of Hematology
基金
国家自然科学基金(81070403)
天津市科技计划项目(09ZCZDSF03800)
科技部国际合作项目(2010DFB30270)作者单位:通信作者:肖志坚,Email:zjxiao@hotmail.eom